RETROSPECTIVE COHORT STUDY OF DRUG UTILIZATION PATTERNS IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS: A COMPARATIVE ANALYSIS OF DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE
Authors/Creators
- 1. M. Pharmacy, Department of Pharmacology, Sri Padmavathi Mahila Visvavidyalayam, Tirupathi-517502.
- 2. M.Pharm, PhD, Department of Pharmacology, Sri Padmavathi Mahila Visvavidyalayam, Tirupathi-517502.
Description
Background: CKD is a progressive, irreversible condition characterised by the gradual decline in kidney function. CKD patients are frequently subjected to polypharmacotherapy for complications and comorbidities, resulting in a significantly high ADRs. It is necessary to achieve the optimal pharmacotherapy taking into account the patterns of drug utilization. Aim: To describe the use of drugs in CKD and study mechanisms of action of frequently prescribed agents at different stages of CKD using an in silico comparative analysis. Methods: Three frequently used drugs (Torsemide, Febuxostat and Furosemide) were studied. The structures of drugs were downloaded in SDF format from PubChem. ADMETlab 3.0 and Lipinski’s Rule of Five were used to evaluate the pharmacokinetic properties and drug-likeness. The target proteins were predicted with Swiss Target Prediction, and the CKD-related genes were all obtained from GeneCards. Intersecting targets were then processed by the STRING and visualized in Cytoscape to identify hub genes. AutoDock Vina was employed for molecular docking and ShinyGO was used for function enrichment analysis. Structures were obtained from RCSB PDB, and pictures of drug-target interactions produced with PyMOL. Results: Network pharmacology analysis identified 205 shared targets and 10 key hub genes (SRC, HSP90AA1, BCL2, PPARG, PTGS2, GSK3B, BCL2L1, MAPK14, RHOA, and MTOR) linked to inflammation, oxidative stress, apoptosis, and metabolic regulation. Major enriched pathways included PI3K-Akt, cAMP, lipid and atherosclerosis, and nitrogen metabolism. Docking studies demonstrated strong binding affinities (−4.3 to −8.8 kcal/mol), with Torsemide showing the highest stability, followed by Febuxostat & Furosemide. Conclusion: The study highlights the importance of multi-target pharmacotherapy in CKD management, with Torsemide demonstrating superior therapeutic potential.
Files
4 WJPSR 2068.pdf
Files
(1.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:c2a1377c55adf703092d1aff8ff9ac50
|
1.8 MB | Preview Download |
Additional details
References
- 1. Ahlawat R, D'cruz S, Tiwari P. Drug utilization pattern in chronic kidney disease patients at a tertiary care public teaching hospital: Evidence from a cross-sectional study. J Pharm Care Health Syst, 2015 Dec 12; 3(1): 1-5.
- 2. Andrassy KM. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'. Kidney international, 2013 Sep 1; 84(3): 622-3.
- 3. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, Adebayo OM, Afarideh M, Agarwal SK, Agudelo-Botero M, Ahmadian E. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet, 2020 Feb 29; 395(10225): 709-33.
- 4. Chen L, Li X, Deng Y, Chen J, Huang M, Zhu F, Gao Z, Wu L, Hong Q, Feng Z, Cai G. The PI3K-Akt-mTOR pathway mediates renal pericyte-myofibroblast transition by enhancing glycolysis through HKII. Journal of Translational Medicine, 2023 May 13; 21(1): 323.
- 5. Dorotea D, Lee S, Lee SJ, Lee G, Son JB, Choi HG, Ahn SM, Ha H. KF-1607, a novel pan src kinase inhibitor, attenuates obstruction-induced tubulointerstitial fibrosis in mice. Biomolecules & Therapeutics, 2020 Jul 21; 29(1): 41.
- 6. Gui Y, Dai C. mTOR signaling in kidney diseases. Kidney360, 2020 Nov 1; 1(11): 1319-27.
- 7. Ibrahim N, Wong IC, Tomlin S, Sinha MD, Rees L, Jani Y. Epidemiology of medication-related problems in children with kidney disease. Pediatric Nephrology, 2015 Apr; 30: 623-33.
- 8. Iftikhar A, Ishtiaq Q, Uzair M, Nazir QA, Ch AS, Khan ZA. Novel Biomarkers in the Early Detection of Chronic Kidney Disease: Current Evidence and Future Directions. Indus Journal of Bioscience Research, 2025 May 25; 3(5): 58-66.
- 9. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Tamura MK, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. American Journal of Kidney Diseases, 2014 May 1; 63(5): 713-35.
- 10. Levey AS, Coresh J. Chronic kidney disease. The lancet, 2012 Jan 14; 379(9811): 165-80.
- 11. Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJ, Jardine M, Kasiske B. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. The Lancet, 2017 Oct 21; 390(10105): 1888-917.
- 12. Li S. Network pharmacology evaluation method guidance-draft. World Journal of Traditional Chinese Medicine, 2021 Jan 1; 7(1): 146-54.
- 13. Ma Y, Shi M, Wang Y, Liu J. PPARγ and its agonists in chronic kidney disease. International Journal of Nephrology, 2020; 2020(1): 2917474.
- 14. Madias JE. Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?. Heart Failure, 2023 May 1; 11(5): 617.
- 15. Matzke GR, Aronoff GR, Atkinson Jr AJ, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT. Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international, 2011 Dec 1; 80(11): 1122-37.
- 16. Qutb SA, Soliman AM, Fahmy SR, Mohamed AS. Renoprotective Effects of Eugenol-Loaded Chitosan Nanoparticles on Septic Rats. Drug Delivery Letters, 2025 Feb 4.
- 17. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, Xu X. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of cheminformatics, 2014 Apr 16; 6(1): 13.
- 18. Wang J, Zhuang S. Src family kinases in chronic kidney disease. American Journal of Physiology-Renal Physiology, 2017 Sep 1; 313(3): F721-8.
- 19. Xiao L, Zhu X, Yang S, Liu F, Zhou Z, Zhan M, Xie P, Zhang D, Li J, Song P, Kanwar YS. Rap1 ameliorates renal tubular injury in diabetic nephropathy. Diabetes, 2014 Apr 1; 63(4): 1366-80.
- 20. Yan Y, Ma L, Zhou X, Ponnusamy M, Tang J, Zhuang MA, Tolbert E, Bayliss G, Bai J, Zhuang S. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney international, 2016 Jan 1; 89(1): 68-81.